Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan

被引：0
|
作者：
Palshof, Jesper Andreas
Christensen, Troels Dreier
Poulsen, Tim Svendstrup
Jensen, Benny Vittrup
Linnemann, Dorte
Schou, Jakob Vasehus
Pfeiffer, Per
Yilmaz, Mette K. N.
Christensen, Ib Jarle
Hogdall, Estrid V.
Nielsen, Dorte
机构：
[1] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Oncol, Herlev, Denmark
[2] Herlev Univ Hosp, Dept Oncol, Herlev, Denmark
[3] Herlev Univ Hosp, Dept Pathol, Herlev, Denmark
[4] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Oncol, Copenhagen, Denmark
[5] Herlev Univ Hosp, Herlev, Denmark
[6] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[7] Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark
[8] Herlev Hosp, Univ Copenhagen, Dept Pathol, Herlev, Denmark
[9] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Pathol, Herlev, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15115
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil
    Pfeiffer, Per
    Nielsen, Dorte
    Yilmaz, Mette
    Iversen, Anja
    Vejlo, Christian
    Jensen, Benny Vittrup
    ACTA ONCOLOGICA, 2007, 46 (05) : 697 - 701
  • [42] Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Rosati, G
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2005, 2 (01): : 20 - 21
  • [43] Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Saltz, LB
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (01): : 20 - 21
  • [44] Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Leonard B Saltz
    Nature Clinical Practice Oncology, 2005, 2 : 20 - 21
  • [45] Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Gerardo Rosati
    Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2 : 20 - 21
  • [46] Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
    Yamaguchi, Toshifumi
    Iwasa, Satoru
    Nagashima, Kengo
    Ikezawa, Nobuaki
    Hamaguchi, Tetsuya
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko
    Kato, Ken
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2016, 36 (07) : 3531 - 3536
  • [47] A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese (OGSG1001).
    Taira, Koichi
    Yoshida, Motoki
    Sugimoto, Naotoshi
    Kii, Takayuki
    Kuwakado, Shin
    Fukunaga, Mutsumi
    Hasegawa, Hiroko
    Kato, Takeshi
    Miyake, Yasuhiro
    Hata, Taishi
    Tokunaga, Yukihiko
    Takeda, Koji
    Daga, Haruko
    Yoshinami, Tetsuhiro
    Shimokawa, Toshio
    Sakai, Daisuke
    Kurokawa, Yukinori
    Satoh, Taroh
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [48] Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.
    Shitara, Kohei
    Yamanaka, Takeharu
    Denda, Tadamichi
    Tsuji, Yasushi
    Shinozaki, Katsunori
    Komatsu, Yoshito
    Kobayashi, Yoshimitsu
    Furuse, Junji
    Okuda, Hiroyuki
    Asayama, Masako
    Akiyoshi, Kohei
    Kagawa, Yoshinori
    Kato, Takeshi
    Oki, Eiji
    Ando, Takashi
    Ohashi, Yasuo
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
    Spindler, Karen-Lise G.
    Pallisgaard, Niels
    Lindebjerg, Jan
    Frifeldt, Sanne K.
    Jakobsen, Anders
    BMC CANCER, 2011, 11
  • [50] EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
    Karen-Lise G Spindler
    Niels Pallisgaard
    Jan Lindebjerg
    Sanne K Frifeldt
    Anders Jakobsen
    BMC Cancer, 11
12345